Loading stock data…
PBYI
$7.14-0.35 (-4.67%)
Market ClosedLast close May 11
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Puma Biotechnology, Inc. in the Healthcare sector is trading at $7.14. The stock is currently near its 52-week high of $7.90, remaining 24.0% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why PBYI maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.14
Potential Upside
87.7%
Whystock Fair Value$13.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Hold
Mean target$5.00-30.0%
Range$5.00 – $5.00
Fundamentals
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$376.49M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.87%
Volume
Today's trading volume
393,247
Recent News
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) just released its latest quarterly results and things are looking bullish...
Puma (PBYI) Q1 2026 Earnings Call Transcript
After the close today, Puma issued a news release detailing results for the first quarter of 2026. Today's conference call will include statements about Puma's future expectations, plans and prospects that constitute forward-looking statements for purposes of federal securities laws.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company’s earnings call. Management attributed the quarter’s product revenue
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary
Moby summary of Puma Biotechnology, Inc.'s Q1 2026 earnings call